stilren

Stilren, also known as stilbestrol, is a synthetic estrogen medication that was widely used in the mid-20th century for various medical purposes. It was first synthesized in 1941 and approved for use in the United States in 1956. Stilren is a nonsteroidal estrogen, meaning it does not have a steroid structure, and it was one of the first synthetic estrogens to be developed.

Stilren was primarily used to treat conditions related to estrogen deficiency, such as menopausal symptoms, osteoporosis, and certain types of anemia. It was also used to promote the development of secondary sexual characteristics in girls and to prevent miscarriage in pregnant women. Additionally, stilren was sometimes prescribed off-label for conditions like breast cancer, although its use for this purpose has been largely discontinued due to concerns about its safety and efficacy.

The medication was marketed under various brand names, including Menostrin, Stilboest, and Stilbestrol. Stilren was administered orally and was available in tablet, capsule, and liquid forms. It was generally well-tolerated, but like all estrogen medications, it carried the risk of side effects such as nausea, breast tenderness, and an increased risk of blood clots and stroke.

In the 1970s, concerns about the safety of stilren emerged, particularly regarding its potential to increase the risk of endometrial cancer. This led to a decline in its use, and by the 1980s, it had largely been replaced by other estrogen medications. Stilren was eventually withdrawn from the market in the United States in 1988 due to safety concerns.

Today, stilren is rarely used and is considered an obsolete medication. Its historical significance lies in its role as one of the first synthetic estrogens and its widespread use in the mid-20th century. However, its safety profile and efficacy have led to its decline in medical practice.